medicina59巻3号

2022年03月発行

特集 成人が必要とするワクチン—生涯を通した予防接種の重要性 成人を予防する代表的なワクチン 〈新型コロナワクチン〉

国内で使用可能な新型コロナワクチン②—接種対象者，有効性および安全性

著者： 守屋章成¹²

所属機関： ¹長崎大学熱帯医学研究所 ²名古屋検疫所中部空港検疫所支所

ページ範囲：P.510 - P.516

Point
◎国内で使用可能なmRNAワクチン2剤およびウイルスベクターワクチン1剤は，いずれも治験第Ⅲ相および市中観察研究の双方で高い感染予防効果および重症化予防効果を示してきた．
◎デルタ株の優勢および経時変化による免疫低下を示す研究が出始めているが，バイアスの可能性も強く，解釈は慎重になるべきである．
◎貧困国の接種割合が未だ低迷しているなかで日本をはじめとする富裕国がブースター接種導入を進めることについて，グローバルな視点からの懸念がある．
◎新型コロナワクチンに関する研究・エビデンスは追加更新が目まぐるしいため，常に最新の情報に当たる必要がある．

参考文献

1）厚生労働省：新型コロナワクチンの有効性・安全性について．　https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_yuukousei_anzensei.html（2021年10月閲覧）

2）日本産科婦人科学会，他：新型コロナウイルス（メッセンジャーRNA）ワクチンについて（第2報）.；2021.　https://www.jsog.or.jp/news/pdf/20210814_COVID19_02.pdf（2021年10月閲覧）

3）Polack FP, et al：Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383：2603-2615, 2020

4）Baden LR, et al：Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384：403-416, 2021

5）Voysey M, et al：Safety and efficacy of the ChAdOx1 nCoV-19 vaccine（AZD1222）against SARS-CoV-2；An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397：99-111, 2021

6）Thomas SJ, et al：Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385：1761-1773, 2021

7）El Sahly HM, et al：Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 385：1774-1785, 2021

8）Falsey AR, et al：Phase 3 safety and efficacy of AZD1222（ChAdOx1 nCoV-19）Covid-19 vaccine. N Engl J Med：NEJMoa2105290, 2021［Online ahead of print］

9）Dagan N, et al：BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384：1412-1423, 2021

10）Tande AJ, et al：Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis：ciab229, 2021［Online ahead of print］

11）Thompson MG, et al：Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers；Eight U.S. locations, December 2020-March. MMWR Morb Mortal Wkly Rep 70：495-500, 2021

12）Hall VJ, et al：Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study（the SIREN Study）. SSRN Electron J 6736：1-11, 2021

13）Haas EJ, et al：Articles impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel；An observational study using national surveillance data. Lancet 397：1819-1829, 2021

14）Tang L, et al：Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA 325：2500-2502, 2021

15）Chodick G, et al：The effectiveness of the two-dose BNT162b2 vaccine；Analysis of real-world data. Clin Infect Dis：ciab438, 2021［Online ahead of print］

16）Voysey M, et al：Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19（AZD1222）vaccine；A pooled analysis of four randomised trials. Lancet 397：881-891, 2021

17）Pritchard E, et al：Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 27：1370-1378, 2021

18）Lopez Bernal J, et al：Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England；Test negative case-control study. BMJ 373：n1088, 2021

19）Hyams C, et al：Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years；A test-negative, case-control study. Lancet Infect Dis 63：1-9, 2021

20）Thompson MG, et al：Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med 385：1355-1371, 2021

21）Self WH, et al：Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen（Johnson ＆ Johnson）vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March-August 2021. MMWR Morb Mortal Wkly Rep 70：1337-1343, 2021

22）Pouwels KB, et al：Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv, 2021［Online ahead of print］

23）Keehner J, et al：Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 385：1330-1332, 2021

24）Levin EG, et al：Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med：NEJMoa2114583, 2021［Online ahead of print］

25）Goldberg Y, et al：Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med：NEJMoa2114228, 2021［Online ahead of print］

26）Chemaitelly H, et al：Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med：NEJMoa2114114, 2021［Online ahead of print］

27）Burki T：Booster shots for COVID-19—the debate continues. Lancet Infect Dis 21：1359-1360, 2021

28）Schaefer GO, et al：Making vaccines available to other countries before offering domestic booster vaccinations. JAMA 326：903-904, 2021

29）Krause PR, et al：Considerations in boosting COVID-19 vaccine immune responses. Lancet 398：1377-1380, 2021

30）Lachish T, et al：Morbidity among the Israeli Defense Force response team during Nepal, post-earthquake mission, 2015. J Travel Med 24：1-5, 2017

31）第25回厚生科学審議会予防接種・ワクチン分科会：資料2　新型コロナワクチンの接種について．　https://www.mhlw.go.jp/content/10601000/000849024.pdf（2021年10月閲覧）

32）Tartof SY, et al：Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA；A retrospective cohort study. Lancet 398：1407-1416, 2021

33）Sheikh A, et al：BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta Variant. N Engl J Med：NEJMc2113864, 2021［Online ahead of print］

34）厚生労働省：新型コロナワクチンの接種後の健康状況調査．　https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_kenkoujoukyoutyousa.html（2021年10月閲覧）

35）Shimabukuro TT, et al：Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US — December 14, 2020-January 18, 2021. JAMA 325：2020-2021, 2021

36）Klein NP, et al：Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326：1390-1399, 2021

37）Ramsay M, eds：COVID-19 - SARS-CoV-2. In：Immunisation against Infectious Disease（the Green Book）, 2021.　https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029750/Greenbook_chapter_14a_29Oct21.pdf（2021年11月閲覧）

38）Abu-Mouch S, et al：Myocarditis following COVID-19 mRNA vaccination. Vaccine 39：3790-3793, 2021

39）Marshall M, et al：Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics 148：e2021052478, 2021

40）Ryan M, et al：Myocarditis following immunization with mrna covid-19 vaccines in members of the us military. JAMA Cardiol 6：1202-1206, 2021

41）Gargano JW, et al：Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients；Update from the Advisory Committee on Immunization Practices — United States, June 2021 Julia. Morb Mortal Wkly Rep Use 70：977-982, 2021

42）Witberg G, et al：Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med：NEJMoa2110737, 2021［Online ahead of print］

43）Simone A, et al：Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older. JAMA Intern Med：e215511, 2021［Online ahead of print］

44）Mevorach D, et al：Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med：NEJMoa2109730, 2021［Online ahead of print］

45）Paterlini M：Covid-19：Sweden, Norway, and Finland suspend use of Moderna vaccine in young people “as a precaution”. BMJ 375：n2477, 2021

46）第70回厚生科学審議会予防接種・ワクチン分科会副反応検，討部会，令和3年度第19回薬事・食品衛生審議会薬事分科，会医薬品等安全対策部会安全対策調査会：資料1-1-1心筋炎関連事象疑い報告の状況について．　https://www.mhlw.go.jp/content/10601000/000844075.pdf（2021年10月閲覧）

47）厚生労働省：新型コロナワクチン接種後の心筋炎・心膜炎について 2021年10月15日．　https://www.mhlw.go.jp/content/000844011.pdf（2021年10月閲覧）

48）Daniels CJ, et al：Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection；Results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol 6：1078-1087, 2021

49）Greinacher A, et al：Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384：2092-2101, 2021

50）Schultz NH, et al：Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384：2124-2130, 2021

51）Scully M, et al：Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384：2202-2211, 2021

52）Abbattista M, et al：Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database；Thrombosis at unusual sites. J Thromb Haemost 19：2554-2558, 2021

53）Pavord S, et al：Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 385：1680-1689, 2021

54）Bourguignon A, et al：Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia. N Engl J Med 385：720-728, 2021

55）Taquet M, et al：Cerebral venous thrombosis and portal vein thrombosis；A retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 39：2-8, 2021

56）厚生労働省健康局健康課予防接種室：アストラゼネカ社ワクチンの接種体制及び流通体制の構築について 事務連絡 令和3年8月3日．　https://www.mhlw.go.jp/content/000815978.pdf（2021年10月閲覧）

57）Shimabukuro TT, et al：Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med 384：2273-2282, 2021

58）Zauche LH, et al：Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med 385：1533-1535, 2021

59）Magnus MC, et al：Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med：NEJMc2114466, 2021［Online ahead of print］

60）Cavanaugh AM, et al：Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May-June 2021. MMWR Recomm Reports 70：1081-1083, 2021

61） Public Health England：SARS-CoV-2 variants of concern and variants under investigation in England；Technical briefing 31.　https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf（2022年1月閲覧）

62） Ferguson N, et al：Report 49；Growth, population distribution and immune escape of Omicron in England.　https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-16-COVID19-Report-49.pdf（2022年1月閲覧）

63） Andrews N, et al：Effectiveness of COVID-19 vaccines against the Omicron（B.1.1.529）variant of concern. medRxiv, Posted December 14, 2021